| Pair Name | Caffeic acid phenethyl ester, Bortezomib | ||
| Phytochemical Name | Caffeic acid phenethyl ester (PubChem CID: 5281787 ) | ||
| Anticancer drug Name | Bortezomib (PubChem CID: 387447 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Caffeic acid phenethyl ester, Bortezomib | |||
| Disease Info | [ICD-11: 2A83] | Multiple myeloma | Investigative | |
| Gene Regulation | Down-regulation | Expression | IL6 | hsa3569 |
| Down-regulation | Activity | NFKB1 | hsa4790 | |
| In Vitro Model | ARH-77 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_1072 |
| In Vivo Model | Female BALB/c mice (5–6 weeks old) were use in this study. | |||
| Result | We think that our study, which is the first to demonstrate the in vitro and in vivo effectiveness of the.combined use of CAPE and bortezomib, will be a pioneer for future human applications of CAPE in MM. | |||
| No. | Title | Href |
|---|---|---|
| 1 | An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells. Turk J Med Sci. 2015;45(1):38-46. doi: 10.3906/sag-1401-127. | Click |
